EX-99.1 2 biol-20210812ex99_1.htm EX-99.1 EX-99.1

 

img24822439_0.jpg

Exhibit 99.1

 

BIOLASE REPORTS SIGNIFICANTLY IMPROVED REVENUE IN ITS SECOND QUARTER AS CONTINUED HIGH DEMAND FOR DENTAL LASERS FROM NEW CUSTOMERS FUELED GROWTH

Guides for Significant Revenue Growth Year-Over-Year in Third Quarter 2021

Foothill Ranch, Calif., August 12, 2021 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for its second quarter ended June 30, 2021 and provided third quarter 2021 revenue guidance.

2021 Second Quarter Operating Highlights (all comparisons are on a year-over-year basis unless specified otherwise):

Net revenue grew 211% to $9.1 million:
o
Over 70% of U.S. laser sales came from new customers, continuing a positive trend
o
Over 35% of U.S. Waterlase sales came from dental specialists
Net revenue was 6% higher than the pre-pandemic revenues during the second quarter of 2019
Laser system sales increased 424%
Consumables and other revenue increased 173%
U.S. and international revenue increased 167% and 340%, respectively, as more dental practices were operating during the 2021 second quarter compared to the year-ago second quarter due to the COVID-19 pandemic
Gross margin was 44%, up 1,200 basis points, due to the higher year-over-year revenue, favorable revenue mix and higher average selling prices for products sold during the quarter
Net loss was $702,000 or $0.00 per share, compared to a net loss of $4.7 million or $0.12 per share a year ago
Maintained strong balance sheet, as cash and cash equivalents totaled $37.1 million at quarter end

 

"Our strong second quarter performance is due to rising demand for our industry-leading dental lasers as a result of our intensified focus on education and training, the increased safety our lasers provide to dentists and their patients, and the published studies highlighting the improved results our laser provides to treat perio-disease,” commented John Beaver, President and Chief Executive Officer.

 

“With over 70% of our U.S. laser sales being generated from new customers during the quarter, and over 35% of our U.S. Waterlase sales coming from dental specialists, it’s clear our messaging, marketing, educational and training efforts are bearing fruit.  However, I believe this is only the beginning because our industry-leading dental lasers provide a better standard of care for dental procedures. In addition, they ensure a safer environment for dental practitioners and patients by reducing aerosolization to mitigate the spread of infectious pathogens, such as COVID-19. Dental practitioners experienced a significant disruption to their business during the peak pandemic period. However, our lasers limit their exposure, from a health and business perspective, which was another contributing factor to our strong turnaround from one year ago."

 

"Our focus on educating and training dental specialists on the benefits of our lasers is already leading to increased adoption across these large and untapped markets. In fact, this momentum is giving us greater visibility into Q3, and we feel comfortable providing guidance regarding expected significant year-over-year improvement across our key performance metrics, including revenue and gross margin,” concluded Mr. Beaver.

 

 

2021 Second Quarter Financial Results

Net revenue for the second quarter of 2021 was $9.1 million, an increase of 211% compared to net revenue of $2.9 million for the second quarter of 2020, which was the quarter impacted the most by the COVID-19 pandemic as many dental practitioners were forced to suspend procedures. U.S. laser revenue was $3.3 million for the second quarter of 2021, up 299% when compared to U.S. laser revenue of $0.8 million for the second quarter of 2020. U.S. consumables and other revenue for the second quarter of 2021, which consists of revenue from consumable products such as disposable tips, increased 258% compared to the second quarter of 2020. Outside the U.S., laser revenue increased 806% to $2.5 million for the second quarter of 2021, compared to $0.3 million for the second quarter of 2020, and consumables and other revenue increased 85% year over year as recovery from the pandemic improved internationally.

Gross margin for the second quarter of 2021 was 44%, compared to 32% for the second quarter of 2020. The higher gross margin reflects the impact of the increase in revenues and increased average selling prices for products sold during the second quarter of 2021. Total operating expenses were $7.3 million for the second quarter of 2021, compared to $4.9 million for the second quarter of 2020. Operating loss for the second quarter of 2021, was $3.3 million, compared to an operating loss of $4.0 million in the second quarter of 2020. Net loss for the second quarter of 2021 was $702,000, or $0.00 per share, compared to a net loss of $4.7 million, or $0.12 per share, for the second quarter of 2020. The improvement in net loss for the quarter was favorably impacted by a $3.0 million gain due to the forgiveness of a Paycheck Protection Program loan during the quarter.

 

Cash, cash equivalents, and restricted cash totaled $37.3 million as of June 30, 2021.

Adjusted EBITDA – Use of Non-GAAP Measures

The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.

Adjusted EBITDA loss for the second quarter of 2021 was $2.7 million, or $0.02 per share, compared to Adjusted EBITDA loss of $2.9 million, or $0.08 per share, for the second quarter of 2020.

2021 Third Quarter Revenue Guidance

The Company continues to experience high demand for its dental lasers and is currently forecasting revenue for the third quarter ending September 30, 2021, to be significantly above the year-ago third quarter despite the pent up demand the Company experienced in last year’s Q3 as procedure volume dramatically improved from historically low levels in the 2020 second quarter. Even though the third quarter of the year is seasonally our second weakest revenue quarter, we expect the third quarter of 2021 to approach revenues we achieved in the second quarter of 2021.

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the second quarter ended June 30, 2021, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is (800) 367-2403. For international participants outside the U.S./Canada, the dial-in number is (334) 777-6978. For all callers, refer to the Conference ID 9019839. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see “Investor Events”.

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and

 

 

healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 271 patented and 40 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding the anticipated effects of our messaging, marketing, educational and training efforts; BIOLASE’s expected revenue, revenue growth and gross margin for the third quarter of 2021; and anticipated cash needs. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “guidance,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the pandemic and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K and quarterly report filed on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

 

For further information, please contact:

BIOLASE, Inc.

John R. Beaver, President and Chief Executive Officer

833-BIOLASE

jbeaver@biolase.com

or

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

Tables to Follow

 

 

 

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited, in thousands, except per share data)

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net revenue

 

$

9,134

 

 

$

2,938

 

 

$

17,250

 

 

$

7,721

 

Cost of revenue

 

 

5,093

 

 

 

1,997

 

 

 

10,469

 

 

 

5,427

 

Gross profit

 

 

4,041

 

 

 

941

 

 

 

6,781

 

 

 

2,294

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

3,311

 

 

 

2,093

 

 

 

6,864

 

 

 

4,797

 

General and administrative

 

 

2,779

 

 

 

2,137

 

 

 

6,134

 

 

 

5,147

 

Engineering and development

 

 

1,162

 

 

 

690

 

 

 

2,966

 

 

 

1,680

 

Loss on patent litigation settlement

 

 

72

 

 

 

—

 

 

 

161

 

 

 

—

 

Total operating expenses

 

 

7,324

 

 

 

4,920

 

 

 

16,125

 

 

 

11,624

 

Loss from operations

 

 

(3,283

)

 

 

(3,979

)

 

 

(9,344

)

 

 

(9,330

)

(Gain) Loss on foreign currency transactions

 

 

(69

)

 

 

40

 

 

 

136

 

 

 

126

 

Interest expense, net

 

 

582

 

 

 

625

 

 

 

1,157

 

 

 

1,214

 

Gain on debt forgiveness

 

 

(3,014

)

 

 

—

 

 

 

(3,014

)

 

 

—

 

Non-operating (gain) loss, net

 

 

(2,501

)

 

 

665

 

 

 

(1,721

)

 

 

1,340

 

Loss before income tax provision (benefit)

 

 

(782

)

 

 

(4,644

)

 

 

(7,623

)

 

 

(10,670

)

Income tax provision (benefit)

 

 

(80

)

 

 

53

 

 

 

(20

)

 

 

34

 

Net loss

 

 

(702

)

 

 

(4,697

)

 

 

(7,603

)

 

 

(10,704

)

Other comprehensive loss items:

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

65

 

 

 

74

 

 

 

(83

)

 

 

56

 

Comprehensive loss

 

$

(637

)

 

$

(4,623

)

 

$

(7,686

)

 

$

(10,648

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(702

)

 

$

(4,697

)

 

$

(7,603

)

 

$

(10,704

)

Deemed dividend on convertible preferred stock

 

 

(6

)

 

 

—

 

 

 

(538

)

 

 

—

 

Net loss attributable to common stockholders

 

$

(708

)

 

$

(4,697

)

 

$

(8,141

)

 

$

(10,704

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.00

)

 

$

(0.12

)

 

$

(0.06

)

 

$

(0.31

)

Diluted

 

$

(0.00

)

 

$

(0.12

)

 

$

(0.06

)

 

$

(0.31

)

Shares used in the calculation of net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

150,665

 

 

 

37,990

 

 

 

142,693

 

 

 

34,709

 

Diluted

 

 

150,665

 

 

 

37,990

 

 

 

142,693

 

 

 

34,709

 

 

 

 

 

BIOLASE, INC.

CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except per share data)

 

 

June 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

37,081

 

 

$

17,564

 

Restricted cash

 

 

204

 

 

 

312

 

Accounts receivable, less allowance of $3,908 and $4,017 in 2021 and 2020,
   respectively

 

 

3,819

 

 

 

3,059

 

Inventory

 

 

12,715

 

 

 

11,157

 

Prepaid expenses and other current assets

 

 

1,521

 

 

 

3,018

 

Total current assets

 

 

55,340

 

 

 

35,110

 

Property, plant, and equipment, net

 

 

916

 

 

 

782

 

Goodwill

 

 

2,926

 

 

 

2,926

 

Right of use asset

 

 

1,842

 

 

 

1,976

 

Other assets

 

 

225

 

 

 

231

 

Total assets

 

$

61,249

 

 

$

41,025

 

LIABILITIES, REDEEMABLE PREFERRED STOCK AND
   STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,502

 

 

$

2,651

 

Accrued liabilities

 

 

6,461

 

 

 

6,667

 

Deferred revenue, current portion

 

 

2,056

 

 

 

1,905

 

Term loan, net of discount

 

 

700

 

 

 

—

 

Total current liabilities

 

 

12,719

 

 

 

11,223

 

Deferred revenue

 

 

333

 

 

 

374

 

Warranty accrual

 

 

507

 

 

 

384

 

Non current term loans, net of discount

 

 

12,703

 

 

 

16,186

 

Non current operating lease liability

 

 

1,602

 

 

 

1,774

 

Other liabilities

 

 

129

 

 

 

1,056

 

Total liabilities

 

 

27,993

 

 

 

30,997

 

Stockholders' equity:

 

 

 

 

 

 

Series F Preferred stock, par value $0.001 per share

 

 

35

 

 

 

118

 

Common stock, par value $0.001 per share

 

 

151

 

 

 

98

 

Additional paid-in capital

 

 

292,517

 

 

 

261,573

 

Accumulated other comprehensive loss

 

 

(468

)

 

 

(385

)

Accumulated deficit

 

 

(258,979

)

 

 

(251,376

)

Total stockholders' equity

 

 

33,256

 

 

 

10,028

 

Total liabilities, redeemable preferred stock and stockholders' equity

 

$

61,249

 

 

$

41,025

 

 

 

 

BIOLASE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2021

 

 

2020

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

Net loss

 

$

(7,603

)

 

$

(10,704

)

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

176

 

 

 

488

 

Provision for bad debts

 

 

(79

)

 

 

1,008

 

Inventory write-offs and disposals

 

 

(103

)

 

 

—

 

Amortization of discount on lines of credit

 

 

84

 

 

 

74

 

Amortization of debt issuance costs

 

 

193

 

 

 

121

 

Patent litigation mark-to-market

 

 

161

 

 

 

—

 

Stock-based compensation

 

 

1,297

 

 

 

1,519

 

Gain on debt forgiveness

 

 

(3,014

)

 

 

—

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(682

)

 

 

3,633

 

Inventory

 

 

(1,455

)

 

 

(937

)

Prepaid expenses and other current assets

 

 

438

 

 

 

(14

)

Accounts payable and accrued liabilities

 

 

471

 

 

 

(3,835

)

Deferred revenue

 

 

108

 

 

 

(692

)

Net cash and cash equivalents used in operating activities

 

 

(10,008

)

 

 

(9,339

)

Cash Flows from Investing Activities:

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(311

)

 

 

(81

)

Net cash and cash equivalents used in investing activities

 

 

(311

)

 

 

(81

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

Proceeds from the sale of common stock

 

 

13,291

 

 

 

3,881

 

Proceeds from the sale of common stock warrants

 

 

—

 

 

 

3,031

 

Payments of equity offering costs

 

 

(6

)

 

 

(991

)

Borrowings on other long-term loans

 

 

—

 

 

 

3,140

 

Borrowings on credit facility

 

 

—

 

 

 

3,000

 

Repayment of credit facility

 

 

—

 

 

 

(3,000

)

Fees paid for debt instruments

 

 

—

 

 

 

(50

)

Proceeds from the exercise of common stock warrants

 

 

16,550

 

 

 

—

 

Payment of debt issuance costs

 

 

(24

)

 

 

—

 

Net cash and cash equivalents provided by financing activities

 

 

29,811

 

 

 

9,011

 

Effect of exchange rate changes

 

 

(83

)

 

 

57

 

Increase (decrease) in cash, cash equivalents and restricted cash

 

 

19,409

 

 

 

(352

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

17,876

 

 

 

6,101

 

Cash, cash equivalents and restricted cash, end of period

 

$

37,285

 

 

$

5,749

 

Supplemental cash flow disclosure:

 

 

 

 

 

 

Cash paid for interest

 

$

886

 

 

$

466

 

Cash received for interest

 

$

29

 

 

$

—

 

Cash paid for income taxes

 

$

130

 

 

$

26

 

Cash paid for operating leases

 

$

263

 

 

$

188

 

Non-cash accrual for capital expenditures

 

$

—

 

 

$

35

 

Non-cash settlement of liability

 

$

510

 

 

$

—

 

Non-cash right-of-use assets obtained in exchange for lease obligation

 

$

48

 

 

$

570

 

Warrants issued in connection with debt instruments

 

$

—

 

 

$

67

 

 

 

 

Non-GAAP Financial Measures

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents.

Adjusted EBITDA is defined as net income (loss) before interest, taxes, depreciation and amortization, loss on patent litigation settlement, stock-based and other non-cash compensation, debt forgiveness, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

 

BIOLASE, INC.

Reconciliation of GAAP Net Loss to Adjusted EBITDA and

GAAP Net Loss Per Share to Adjusted EBITDA Per Share

(Unaudited, in thousands, except per share data)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

GAAP net loss attributable to common stockholders

 

$

(708

)

 

$

(4,697

)

 

$

(8,141

)

 

$

(10,704

)

Deemed dividend on convertible preferred stock

 

 

6

 

 

 

—

 

 

 

538

 

 

 

—

 

GAAP net loss

 

$

(702

)

 

$

(4,697

)

 

$

(7,603

)

 

$

(10,704

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

582

 

 

 

625

 

 

 

1,157

 

 

 

1,214

 

Income tax provision (benefit)

 

 

(80

)

 

 

53

 

 

 

(20

)

 

 

34

 

Depreciation and amortization

 

 

91

 

 

 

307

 

 

 

176

 

 

 

488

 

Change in allowance for doubtful accounts

 

 

27

 

 

 

22

 

 

 

(79

)

 

 

1,008

 

Loss on patent litigation settlement

 

 

72

 

 

 

—

 

 

 

161

 

 

 

—

 

Stock-based and other non-cash compensation

 

 

369

 

 

 

801

 

 

 

1,297

 

 

 

1,519

 

Gain on debt forgiveness

 

 

(3,014

)

 

 

—

 

 

 

(3,014

)

 

 

—

 

Adjusted EBITDA

 

$

(2,655

)

 

$

(2,889

)

 

$

(7,925

)

 

$

(6,441

)

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss attributable to common stockholders
   per share, basic and diluted

 

$

—

 

 

$

(0.12

)

 

$

(0.06

)

 

$

(0.31

)

Deemed dividend on convertible preferred stock

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

GAAP net loss per share, basic and diluted

 

$

—

 

 

$

(0.12

)

 

$

(0.06

)

 

$

(0.31

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

—

 

 

 

0.02

 

 

 

0.01

 

 

 

0.03

 

Income tax provision (benefit)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Depreciation and amortization

 

 

—

 

 

 

0.01

 

 

 

—

 

 

 

0.01

 

Change in allowance for doubtful accounts

 

 

—

 

 

 

—

 

 

 

—

 

 

 

0.03

 

Loss on patent litigation settlement

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Stock-based and other non-cash compensation

 

 

—

 

 

 

0.01

 

 

 

0.02

 

 

 

0.05

 

Gain on debt forgiveness

 

 

(0.02

)

 

 

—

 

 

 

(0.02

)

 

 

—

 

Adjusted EBITDA per share, basic and diluted

 

$

(0.02

)

 

$

(0.08

)

 

$

(0.05

)

 

$

(0.19

)